Industry Outlook

Continuous Glucose Monitoring (CGM) System market accounted for USD 7.5 Billion in 2024 and is expected to reach USD 28.2 Billion by 2035, growing at a CAGR of around 12.8% between 2025 and 2035. The Continuous Glucose Monitoring (CGM) system market revolves around systems designed to track glucose levels in real-time, providing constant feedback to individuals with diabetes. CGM systems typically consist of a small sensor inserted under the skin, a transmitter, and a receiver or smartphone app. Whereas traditional glucose meters require patients to perform fingerstick tests and take measurements at periodic intervals. CGMs provide a more holistic picture of glucose trends and patterns throughout the day. This continuous feedback allows users, and their healthcare team, to make more informed decisions about insulin dosing and lifestyle modifications. The market for CGMs has grown based on the increasing prevalence of diabetes and other types of chronic diseases, technology improvements, and greater awareness of the benefits of real-time glucose information.

Report Scope:

Market Dynamics

• The Rising Incidence Of Diabetes, Particularly Type 1 And Type 2, Is A Major Driver For Continuous Glucose Monitoring (CGM) Systems.

A key factor influencing the growth of the Continuous Glucose Monitoring (CGM) system market is the prevalence of diabetes, specifically Type 1 and Type 2 diabetes. The World Health Organization (WHO) estimates that more than 422 million people around the world have diabetes, and worldwide prevalence is increasing. In the United States, the Centers for Disease Control and Prevention (CDC) reports that more than 37 million Americans have diabetes, with greater than 90% of cases classified as Type 2 diabetics.

The increasing diabetic population creates the need for improved monitoring capabilities to better manage glucose levels and acutely mitigate complications. CGM systems provide glucose readings in real-time, which facilitates enhanced management of glucose levels. Thus, the increasing rates of diabetes lead to increased demand for CGM technology and will likely catalyze higher demand in the CGM market.

• High Costs Limit Accessibility, Particularly In Low-Income And Uninsured Populations.

The high cost of Continuous Glucose Monitoring (CGM) systems is a major barrier to accessing this technology among low-income and uninsured individuals. While CGM systems allow patients to get real-time glucose information to manage diabetes more effectively, the high cost includes not just the initial device cost but also the ongoing replacements of sensors and transmitters. The cost can be high for individuals who do not have adequate insurance or have limited financial resources.

As a result, many people who could benefit from CGMs' improved glucose management are unable to access this technology, perpetuating health inequities in diabetes management. The financial burden inhibits the widespread use of CGM systems and highlights the need for lower-cost alternatives that improve access and health outcomes across varying socioeconomic statuses.

• Advancements In Non-Invasive And Minimally Invasive Sensor Technologies Offer Opportunities To Develop More Comfortable And User-Friendly CGM Systems.

Innovations in non-invasive and minimally invasive sensor technologies offer a tremendous opportunity to develop more comfortable and user-friendly Continuous Glucose Monitoring (CGM) systems. It can significantly lessen or eliminate fingerstick calibrations and painful sensor insertion, thus increasing comfort and adherence. Non-invasive sensors intend to lessen the non-comfort of the device attaching to the body and function by a method of optical or electromagnetic detection. All this is done without penetrating the skin to easily have glucose levels monitored.

On the other hand, minimally invasive sensors intend to lessen the invasiveness of the sensor being inserted into the body. Both types of sensors would enhance CGM systems that are likely more convenient and potentially more accepted in person by the patient. Ultimately, advances in the non-invasive and minimally invasive sensor will allow for greater glycemic control and an improved quality of life.

Industry Experts Opinion

“CGMs coupled with personalized education and coaching provided by chronic care management leaders like CCS can make a real difference in the lives of people with diabetes. Focusing on individual goals and small changes that add up over time, this approach can simplify diabetes care and help people achieve better health outcomes.”

• Arti Masturzo, Chief Medical Officer At CCS

“The experience of using a CGM for the first time was extremely empowering but, simultaneously, very hard to understand due to the complexity of the data being measured. The data itself was powerful — for the first time, our bodies were talking to us…and the sound was loud.”

• Anttoni Aniebonam, Veri’s Co-founder

Segment Analysis

By Technology segment, Real-Time Continuous Glucose Monitoring or rtCGM allows rapid, continuous readings of glucose values as well as alerts about high glucose (hyperglycemia) or low glucose (hypoglycemia) levels. This classification of glucose monitoring is often used by people with diabetes who are interested in frequent glucose monitoring and data in real-time to advise their treatment decisions. Flash Glucose Monitoring or FGM systems, such as Abbott's FreeStyle Libre, monitor glucose values are only available when the sensor is actively scanned. While FGM systems are popular and widely used due to their convenience and cost-effectiveness, they generally do not provide the same level of real-time monitoring and alerts as rtCGM systems.

By Application segment, Type 2 diabetes represents the most common form of diabetes, and in fact represents the majority of diabetes cases worldwide. This type of diabetes is often associated with lifestyle and social risk factors and is encountered in adult patients much more frequently than in younger people. However, recently there has been an increase in Type 2 diabetes diagnoses among the younger population because of rising obesity rates. Type 1 diabetes is less common but is an equally important form of diabetes as it is an autoimmune reaction typically diagnosed in childhood. Gestational diabetes occurs during pregnancy, and while it represents a smaller population group than Type 1 and Type 2 diabetes, it may increase an individual’s risk of developing Type 2 diabetes later in life. Type 2 diabetes makes up the largest percentage of patients in the diabetes market due to the frequency of diagnosis and the expanding obesity problem globally.

Regional Analysis

The market for Continuous Glucose Monitoring (CGM) systems in North America is rapidly expanding due increasing prevalence of diabetes in the region. According to the Centers for Disease Control and Prevention (CDC), Approximately 37 million Americans are affected by diabetes, indicating a high demand for sophisticated glucose monitoring. CGM systems provide real-time glucose monitoring as well as superior management, making them increasingly appealing to patients and healthcare providers.

This surge in demand is further fueled by breakthroughs in technology that enhance the accuracy and ease of use of CGM devices. As a result, the market is growing at an exceptional rate, with established and emerging organizations eager to capture part of the market in this emerging market.

Competitive Landscape

In the competitive landscape of the Continuous Glucose Monitoring (CGM) system market, Key players include Dexcom, Abbott Laboratories, and Medtronic. Dexcom's G6 and G7 systems claim to be the most advanced real-time measurement tools for glucose levels, combining innovative new features such as automatic notifications. Abbott's Freestyle Libre series provides many of the same synchronous measures and is affordably priced with an ease-of-use focus. Medtronic provides another standout with the addition of insulin pump integrations for synchronous care with their Guardian Connect CGM system. Other notable competitors include Senseonics, which is known for its implantable Eversense CGM. Similarly, Roche is developing their presence in the CGM space with integrated diabetes management options. The market is characterized by rapid technological advancements and increasing adoption driven by rising diabetes prevalence and demand for personalized healthcare solutions.

Continuous Glucose Monitoring (CGM) System Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In Sept 2024, Hello Inside acquired a total of €1.65 million in funding with a focus on metabolic health for women through continuous glucose monitoring (CGM) data. The aim is to improve health insights and provide interventions.
• In July 2024, Roche's AI-powered glucose monitoring system received CE marking, indicating compliance with health and safety requirements in Europe. The certification allows this innovative technology to be marketed and utilized across European Union countries and territories.
• In August 2024, Dexcom's new over-the-counter glucose monitor, Stelo, costs $99 for a one-month supply or $89 per month with a subscription. It's aimed at 125 million Americans with prediabetes or Type 2 diabetes not on insulin, helping them track how diet, exercise, and stress affect glucose levels. The device is FSA and HSA-eligible.
• In May 2024, Beurer India launched a novel blood glucose lecturing gadget, aiding to effectively manage blood sugar. The gadget was designed to increase an individual's ability to monitor their health more thoroughly and improve health-gadget options for individuals managing diabetes.

Report Coverage:

By Product Type

• Sensors
• Transmitters
• Receivers

By Application

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

By Technology

• Real-Time Continuous Glucose Monitoring (rtCGM)
• Flash Glucose Monitoring (FGM)

By Age Group

• Pediatric Patients
• Adult Population
• Geriatric Population

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online

By End User

• Hospitals & Clinics
• Diagnostic Centers
• Homecare Settings
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Abbott Laboratories
• Dexcom, Inc.
• Medtronic plc
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Novo Nordisk
• Senseonics Holdings, Inc.
• A. Menarini Diagnostics
• Bayer AG
• GE Healthcare
• Insulet Corporation
• LifeScan
• Ypsomed AG
• GlySens Incorporated
• Microchip Technology Inc.
• STMicroelectronics
• Medtrum Technologies, Inc.
• Nemaura Medical, Inc.
• Signos, Inc.
• Qualcomm

Frequently Asked Questions (FAQs)